Travoprost/timolol fixed combination in the management of open-angle glaucoma: a clinical review

Bibliography

• Friedman DS, Wolfs RC, O'Colmain BJ, Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532-8
   PubMed Web of Science ®Google Scholar
• Mason RP, Kosoko O, Wilson MR, National survey of the prevalence and risk factors of glaucoma in St. Lucia, West Indies. Part I. Prevalence findings. Ophthalmology 1989;96:1363-8
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Kass MA, Gordon MO, Gao F, Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol 2010;128:276-87
   PubMedGoogle Scholar
• Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007;24:1007-16
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5
   PubMedGoogle Scholar
• Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol 2010;4:1-9
   PubMedGoogle Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:863-8
   PubMed Web of Science ®Google Scholar
• Fristrom B, Uusitalo H. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension. Acta Ophthalmol 2010;88:37-43
   PubMed Web of Science ®Google Scholar
• Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 2004;137:S13-16
   PubMed Web of Science ®Google Scholar
• Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004;137:S3-12
   PubMed Web of Science ®Google Scholar
• Reardon G, Schwartz GF, Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol 2003;13(Suppl 4):S44-52
   Google Scholar
• Dasgupta S, Oates V, Bookhart BK, Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care 2002;8:S255-61
   PubMed Web of Science ®Google Scholar
• Netland PA, Landry T, Sullivan EK, Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
   PubMed Web of Science ®Google Scholar
• Goldberg I, Cunha-Vaz J, Jakobsen JE, Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001;10:414-22
   PubMed Web of Science ®Google Scholar
• Fellman RL, Sullivan EK, Ratliff M, Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 2002;109:998-1008
   PubMed Web of Science ®Google Scholar
• Nieminen T, Lehtimaki T, Maenpaa J, Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest 2007;67:237-45
   PubMed Web of Science ®Google Scholar
• Merck & Co. Timoptic Prescribing Information, 2005
   Google Scholar
• Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol 2002;134:749-60
   PubMed Web of Science ®Google Scholar
• Soll DB. Evaluation of timolol in chronic open-angle glaucoma. Once a day vs twice a day. Arch Ophthalmol 1980;98:2178-81
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Orengo-Nania S, Flowers BE, The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005;140:1-7
   PubMed Web of Science ®Google Scholar
• Schuman JS, Katz GJ, Lewis RA, Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005;140:242-50
   PubMed Web of Science ®Google Scholar
• Hughes BA, Bacharach J, Craven ER, A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma 2005;14:392-9
   PubMed Web of Science ®Google Scholar
• Gross RL, Sullivan EK, Wells DT, Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%. Clin Ophthalmol 2007;1:317-22
   PubMedGoogle Scholar
• Konstas AG, Mikropoulos D, Haidich AB, Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol 2009;93:481-5
   PubMed Web of Science ®Google Scholar
• Cox JA, Mollan SP, Bankart J, Robinson R. Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. Br J Ophthalmol 2008;92:729-34
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Bracchino M, Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study. Expert Opin Pharmacother 2009;10:1705-11
   PubMed Web of Science ®Google Scholar
• Rhee DJ, Peace JH, Mallick S, A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2008;2:313-19
   PubMedGoogle Scholar
• Denis P, Lafuma A, Jeanbat V, Intraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations: a retrospective, multicentre, cross-sectional study. Clin Drug Investig 2008;28:767-76
   PubMed Web of Science ®Google Scholar
• Topouzis F, Melamed S, Danesh-Meyer H, A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007;17:183-90
   PubMed Web of Science ®Google Scholar
• Konstas AG, Mikropoulos DG, Embeslidis TA, 24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. Eye (Lond) 2010;24:1606-13
   PubMed Web of Science ®Google Scholar
• Teus MA, Miglior S, Laganovska G, Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2009;3:629-36
   PubMedGoogle Scholar
• Arend KO, Raber T. Observational study results in glaucoma patients undergoing a regimen replacement to fixed combination travoprost 0.004%/timolol 0.5% in Germany. J Ocul Pharmacol Ther 2008;24:414-20
   PubMed Web of Science ®Google Scholar
• Pfeiffer N, Scherzer ML, Maier H, Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy. Clin Ophthalmol 2010;4:459-66
   PubMedGoogle Scholar
• Hollo G, Kothy P. Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma. Curr Med Res Opin 2008;24:1755-61
   PubMed Web of Science ®Google Scholar
• Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-52
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Invernizzi T, Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:2566-73
   PubMed Web of Science ®Google Scholar
• Konstas AG, Tsironi S, Vakalis AN, Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Acta Ophthalmol 2009;87:71-6
   PubMed Web of Science ®Google Scholar
• Denis P, Andrew R, Wells D, Friren B. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Eur J Ophthalmol 2006;16:407-15
   PubMed Web of Science ®Google Scholar
• Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008;53(Suppl 1):S93-105
   PubMed Web of Science ®Google Scholar
• Honrubia F, Garcia-Sanchez J, Polo V, Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol 2009;93:316-21
   PubMed Web of Science ®Google Scholar
• Vinuesa-Silva JM, Vinuesa-Silva I, Pinazo-Duran MD, Development of conjunctival hyperemia with the use of a fixed combination of latanoprost/timolol: systematic review and meta-analysis of clinical trials. Arch Soc Esp Oftalmol 2009;84:199-207
   PubMedGoogle Scholar
• Denis P, Covert D, Realini A. Travoprost in the management of open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2007;1:11-24
   PubMedGoogle Scholar
• Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119-26
   PubMed Web of Science ®Google Scholar
• De Saint Jean M, Debbasch C, Brignole F, Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res 2000;20:85-94
   PubMed Web of Science ®Google Scholar
• Baudouin C, Pisella PJ, Fillacier K, Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999;106:556-63
   PubMed Web of Science ®Google Scholar
• Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther 2008;25:743-51
   PubMed Web of Science ®Google Scholar
• Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 2008;27:339-43
   PubMed Web of Science ®Google Scholar
• Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004;23:490-6
   PubMed Web of Science ®Google Scholar
• Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther 2006;23:663-71
   PubMed Web of Science ®Google Scholar
• Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol 1996;7:80-6
   PubMedGoogle Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 2010;29:618-21
   PubMed Web of Science ®Google Scholar
• Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 2007;48:4123-8
   PubMed Web of Science ®Google Scholar
• Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther 2006;23:511-19
   PubMed Web of Science ®Google Scholar
• Labbe A, Pauly A, Liang H, Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 2006;22:267-78
   PubMed Web of Science ®Google Scholar
• Realini T, Fechtner RD. 56,000 ways to treat glaucoma. Ophthalmology 2002;109:1955-6
   PubMed Web of Science ®Google Scholar
• Asrani S, Zeimer R, Wilensky J, Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9:134-42
   PubMed Web of Science ®Google Scholar
• Lee PP, Walt JW, Rosenblatt LC, Association between intraocular pressure variation and glaucoma progression: data from a United States chart review. Am J Ophthalmol 2007;144:901-7
   PubMed Web of Science ®Google Scholar
• Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention Study. Ophthalmology 2008;115:1123-9e3
   Google Scholar
• Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology 2007;114:205-9
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Martin D, Callanan D, Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-7
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr, Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-46 e3
   PubMed Web of Science ®Google Scholar
• Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009;87:450-4
   PubMed Web of Science ®Google Scholar